Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay(The University of Texas MD Anderson Cancer Center), Lauren A. Byers(The University of Texas MD Anderson Cancer Center), Paul Robson(Jackson Laboratory), Simon Heeke(The University of Texas MD Anderson Cancer Center), Bingnan Zhang(The University of Texas MD Anderson Cancer Center), Giulia Fabbri(University of Padua), Elizabeth M. Park(The University of Texas MD Anderson Cancer Center), Barzin Y. Nabet(Gene Therapy Laboratory), Qi Wang(Tongji University), Sarah M. Groves(University of Virginia), C. Allison Stewart(The University of Texas MD Anderson Cancer Center), Jack A. Roth(The University of Texas MD Anderson Cancer Center), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Kavya Ramkumar(The University of Texas MD Anderson Cancer Center), Carminia Maria Della Corte(University of Campania "Luigi Vanvitelli"), John V. Heymach(The University of Texas MD Anderson Cancer Center), John D. Minna(Center for Neuro-Oncology), David S. Shames(Gene Therapy Laboratory), Robert J. Cardnell(The University of Texas MD Anderson Cancer Center), Stephen G. Swisher(The University of Texas MD Anderson Cancer Center), Yuanxin Xi(The University of Texas MD Anderson Cancer Center), Junya Fujimoto(The University of Texas MD Anderson Cancer Center), Natalie I. Vokes(The University of Texas MD Anderson Cancer Center), Lixia Diao(The University of Texas MD Anderson Cancer Center), Kasey R. Cargill(The University of Texas MD Anderson Cancer Center), Jing Wang(The University of Texas MD Anderson Cancer Center), Bonnie S. Glisson(The University of Texas MD Anderson Cancer Center), Vito Quaranta(Northeastern University), Luisa M. Solis(The University of Texas MD Anderson Cancer Center), Wei Lü(The University of Texas MD Anderson Cancer Center)
Cited by 930
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k